AbbVie, OSE Immunotherapeutics Strike Deal to Develop Monoclonal Antibody for Chronic Inflammation

Image Credit: Adobe Stock Images/ipopba

AbbVie and OSE Immunotherapeutics announced that they have agreed to terms on a strategic partnership, focusing on the development of OSE-230, a novel monoclonal antibody aimed at treating chronic and severe inflammation. OSE-230 is a potential first-in-class therapy targeting ChemR23 to activate a distinctive tool that supports chronic inflammation.

Regarding terms of the deal, AbbVie will receive an exclusive global license for the development, manufacturing, and commercialization of OSE-230, while OSE Immunotherapeutics will receive $48 million upfront, with the opportunity to receive up to an additional $665 million based on achieving certain developmental, regulatory, and commercial milestones, plus tiered royalties on future global net sales.¹

“This collaboration underscores our commitment to expanding our immunology portfolio with the ultimate goal of improving the standard of care for patients living with inflammatory diseases globally," said Jonathon Sedgwick, PhD, SVP, global head of discovery research, AbbVie, in a press release. "By leveraging our expertise in immunology drug development, we look forward to advancing OSE-230, which offers a novel mechanism-of-action to treat chronic inflammation."

OSE first presented data supporting OSE-230 as a novel monoclonal antibody for chronic inflammation in October 2020. Data showed that the treatment induces resolution in vivo for inflammation by triggering pro-resolutive programs in macrophages and neutrophils where the inflammation is occurring. Additionally, OSE found that the treatment offers satisfactory relief in type 1 diabetes and multiple sclerosis models, according to the study investigators.²

“OSE-230 represents a disruptive concept in the resolution of inflammation, a failed process in potentially all chronic inflammatory diseases. The data presented show that OSE-230 is the first monoclonal antibody triggering the activation of specialized receptors of resolution to restore tissue homeostasis, integrity, and functions,” said Nicolas Poirier, chief scientific officer, OSE Immunotherapeutics,” in a press release. “Chronic inflammatory diseases are the most significant cause of death worldwide and their incidence is growing, highlighting the patients’ need for disruptive innovations to manage such complex diseases. Our findings provide strong evidence for the therapeutic potential of OSE-230 to be developed in various chronic inflammation and autoimmune pathologies and reinforce OSE’s position in the immunotherapy field targeting myeloid cells in autoimmune and chronic inflammatory diseases and in immuno-oncology.”

OSE’s key findings included natural resolution of inflammation being prompted through pro-resolving lipids, identifying ChemR23 as a GPCR receptor of the resolution program using transcriptional analyses of up to 300 chronic colitis patients, and that the ChemR23 receptor is mainly expressed by resident tissue macrophages and neutrophils only under inflammatory (TNF, IL-6, LPS) conditions.²

References

1. AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation. AbbVie. February 28, 2024. Accessed February 28, 2024.

2. OSE Immunotherapeutics Presents OSE-230 as a Novel Agonist Monoclonal Antibody Therapy Triggering Resolution of Chronic Inflammation. OSE. October 30, 2020. Accessed February 28, 2024. https://www.ose-immuno.com/wp-content/uploads/2021/10/EN_201030__FOCIS-Presentation.pdf